Navigation Links
OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Impressive Results in Higher Risk Patients
Date:4/22/2009

Next Generation Pro-Healing Technology Developments Unveiled

SEOUL, South Korea, April 22 /PRNewswire/ -- OrbusNeich's pro-healing stent technology was featured at a symposium during Angioplasty Summit TCT Asia Pacific 2009 at the Convention Center of Sheraton Grande Walkerhill Hotel in Seoul, South Korea.

Presented by Margo Klomp, MD from the Academic Medical Center (AMC), Amsterdam, The Netherlands, final adjudicated 12 month follow up results from the randomized AMC single center TRIAS High Risk (HR) study showed a slightly higher target lesion revascularization (TLR) rate with the Genous treated patient group compared with patients receiving the Taxus drug eluting stent, but there were no stent thrombosis events at any time period in the 98 patient Genous group with only one month of dual antiplatelet therapy (DAPT). In the 95 patient Taxus cohort, the stent thrombosis rate was 4.2%, including late stent thromboses at 155 and 200 days, even though all patients were on DAPT at the time of stent thrombosis. Furthermore, the composite of death and myocardial infarction for Genous was 4.1% versus 7.3% for Taxus. "Within a month we will complete two year follow up on these patients and we anticipate these results will hold up longer term," said Klomp.

In a separate study involving 446 consecutive patients presented with an acute myocardial infarction (AMI) treated with Genous, Harry Suryapranata, MD, PhD, from Isala Klinieken in Zwolle, The Netherlands, presented 30 day follow up with only one patient (0.2%) having a stent thrombosis. Suryapranata commented, "This rate is impressively low given the highly thrombotic environment associated with AMI patients." Longer term follow up is ongoing.

Juan F Granada, MD, medical director of the Skirball Center for Cardiovascular Research at Columbia University Medical Center, presented results from pre-clinical models demonstrating the effectiveness in combining OrbusNeich's pro-healing cell capture with their fully absorbable drug elution technologies to address the shortcomings with current drug eluting stents (DES), namely the safety concerns associated with the delay and often lack of endothelialization. "In multiple models we have results indicating that this new technology appears to effectively regulate neo-intimal growth, while at the same time promotes the restoration of the arterial wall," explained Granada. These studies highlight the development progress with the next generation of pro-healing drug eluting stent (SES) featuring a combination of endothelial progenitor cell (EPC) capture technology and the abluminal deposition of a fully-absorbable sirolimus eluting matrix.

"Each of these complex technologies on their own offer solutions to the interventionalist," said Seung-Jung Park, MD, PhD, chairperson of the symposium. "By integrating these onto one innovative platform, OrbusNeich is making tremendous strides in being able to offer a single stent addressing multiple concerns."

Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's EPCs to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent, providing a safe and effective alternative to DES.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Other products in the company's product portfolio are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent, Scoreflex(TM), SafeCut(TM), Sapphire(TM), Sapphire NC, Avita(TM), Avita HP, and Lumina(TM).

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, FL; Hoevelaken, The Netherlands; Tokyo, Japan; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit www.orbusneich.com.


'/>"/>
SOURCE OrbusNeich
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Interim Analysis of Data from e-HEALING Registry of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 2008
2. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
3. Finesse Demonstrates TruFluor(TM) pH, a Single-Use Optical pH Sensor and Transmitter
4. VAP Test Demonstrates Value of Fish Oil in Reducing Heart Risk for Super Bowl Champs
5. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
6. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
7. Sparta Systems Demonstrates Global Enterprise Quality Management Leadership at TrackWise(R) Connection User Conferences
8. Human clinical study demonstrates superior Neptune Krill Oil NKO(R) pharmacokinetic profile
9. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
10. RVX-208 Data Demonstrates Increase in Functional HDL Particles
11. Study From the University of Texas M.D. Anderson Cancer Center Demonstrates That AHCC(R) is Safe in Combination With Most Chemotherapeutic Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... -- UCHealth ( Aurora, Colorado ) becomes ... patient management. In addition to optimizing care coordination for ... lung, UCHealth looks to improve provider workflow by decreasing ... Stephanie Brown, RN , Thoracic Nurse Navigator, says, ... Excel spreadsheet, which was extremely arduous and susceptible to ...
(Date:2/16/2017)... N.J. , Feb. 16, 2017  Champions Oncology, ... in the development and sale of advanced technology solutions ... oncology drugs, today announced the addition of new cohorts ... These new models will expand Champions, product line ... head and neck cancer, AML, and non-small cell lung ...
(Date:2/16/2017)... 2017  Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, announced ... showed that aerosolized KL4 surfactant reduced lung inflammation ... animal model. The Company believes that these preclinical ... that supports the role of KL4 surfactant as ...
(Date:2/16/2017)... , Feb. 16, 2017 Paradigm Diagnostics ... B financing, adding an additional $3M from New Sciences ... Verde Venture Partners and other strategic partners at the ... further accelerating commercial adoption of their flagship Paradigm Cancer ... expanding the Paradigm cancer registry. Dr. ...
Breaking Biology Technology:
(Date:1/13/2017)... Jan. 13, 2017 Sandata Technologies, LLC, ... the homecare industry, including Electronic Visit Verification™ (EVV™), ... Justin Jugs, as Senior Vice President of Product ... years of homecare experience to Sandata, where he ... plans to align Sandata,s suite of solutions with ...
(Date:1/12/2017)... , Jan. 12, 2017  New research undertaken by ... of the future.  1,000 participants were simply asked which office ... which we may consider standard issue.  Insights on what ... were also gathered from futurists and industry leaders including ... James Canton .  Some of these ...
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a leading ... the release of its patent-pending calibration device. With this ... perform calibrations, securely upload data logs and process repairs ... customer. "Fighting drunk driving through the application ... public at large, but also for the customer who ...
Breaking Biology News(10 mins):